DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

May 26, 2026 updated by: Boehringer Ingelheim

DAREON™-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)

This study is open to adults aged 18 and older or above legal age who have a specific type of advanced neuroendocrine cancer (NEC). Their tumours must be positive for a marker called DLL3.

The purpose of this study is to test a medicine called BI 764532 in addition to chemotherapy. The study has Part A1, Part A2, and Part B. Part A1 of this study aims to find out the highest dose of BI 764532 that people can tolerate in addition to chemotherapy. Part A2 of this study is to find out how well people tolerate a low dose of BI 764532 combined with the chemotherapy. The purpose of Part B is to find out how well people can tolerate BI 764532 in combination with different chemotherapies. Researchers also want to find out whether BI 764532 in combination with chemotherapy helps people with NEC.

Participants get different doses of BI 764532 as an infusion into a vein. In addition, they get platinum-based chemotherapy as infusions into a vein. Participants can continue treatment up to 3 years if they benefit from treatment and can tolerate it.

Participants visit their doctors regularly. During these visits, the doctors collect information about participants' health and take note of any unwanted effects. Doctors also regularly check the size of the tumour.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

55

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Belgium
      • Brussels, Belgium, 1200
        • Recruiting
        • Cliniques Universitaires Saint-Luc
        • Contact:
  • France
      • Bron, France, 69500
        • Not yet recruiting
        • Hôpital Louis Pradel
        • Contact:
      • Marseille, France, 13009
  • Germany
      • München, Germany, 81377
        • Not yet recruiting
        • Klinikum der Universität München AÖR
        • Contact:
      • Tübingen, Germany, 72076
  • Japan
      • Aichi, Nagoya, Japan, 464-8681
        • Active, not recruiting
        • Aichi Cancer Center Hospital
      • Chiba, Kashiwa, Japan, 277-8577
        • Active, not recruiting
        • National Cancer Center Hospital East
      • Osaka, Osaka, Japan, 541-8567
        • Active, not recruiting
        • Osaka International Cancer institute
      • Tokyo, Chuo-ku, Japan, 104-0045
        • Active, not recruiting
        • National Cancer Center Hospital
  • Netherlands
      • Groningen, Netherlands, 9713 GZ
        • Recruiting
        • Universitair Medisch Centrum Groningen
        • Contact:
  • Spain
      • Barcelona, Spain, 08035
        • Recruiting
        • Hospital Universitari Vall d'Hebron
        • Contact:
      • Madrid, Spain, 28041
        • Recruiting
        • Hospital Universitario 12 de Octubre
        • Contact:
      • Madrid, Spain, 28046
        • Recruiting
        • Hospital Universitario La Paz
        • Contact:
  • Sweden
      • Gothenburg, Sweden, 413 46
        • Recruiting
        • Sahlgrenska Universitetsjukhuset
        • Contact:
      • Uppsala, Sweden, 751 85
        • Not yet recruiting
        • Uppsala University Hospital
        • Contact:
  • United States
    • Florida
      • Miami, Florida, United States, 33136
    • Georgia
      • Atlanta, Georgia, United States, 30322
    • Illinois
      • Chicago, Illinois, United States, 60611
    • New Jersey
      • Hackensack, New Jersey, United States, 07601
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15232

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female participants ≥18 years old and at least at the legal age of consent in countries where it is greater than 18 years at the time of signature of the informed consent form (ICF)
  • Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to any trial-specific procedures, sampling, or analyses

  • Patients diagnosed with locally advanced or metastatic NEC of following subtypes:

    • extrapulmonary neuroendocrine carcinomas (epNEC)
    • pulmonary large cell NEC (LCNEC)
    • neuroendocrine carcinomas (NEC) of unknown primary site
  • Patients with tumours with mixed histologies for any above type are eligible only if neuroendocrine carcinoma/small tumour cells component is predominant and represent at least 50% of the overall tumour tissue
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Minimum life expectancy of 12 weeks
  • At least one measurable lesion as defined per RECIST 1.1 within approximately 35 days prior to the first dose of BI 764532

  • Patients with a history of asymptomatic Central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria:

    • No radiotherapy (including whole brain radiation therapy, stereotactic radiotherapy or radiosurgery) within 7 days
    • Are neurologically stable without the need for steroids or anti-convulsants for at least 7 days before first dose of BI 764532 as per local site assessment Further inclusion criteria apply.

Exclusion Criteria:

  • Previous treatment in this trial
  • Current enrolment in another investigational device or drug trial, or <30 days since ending another investigational device or drug trial(s)
  • Patients with diagnosis of Merkel cell carcinoma or medullary thyroid carcinoma or Grade 3 neuroendocrine tumour
  • Presence of leptomeningeal carcinomatosis
  • Previous treatment with DLL3-targeting T cell engagers and cell therapies
  • Patients who have been treated with extensive field radiotherapy including whole brain irradiation within 2 weeks prior to first administration of BI 764532
  • Major surgery (major according to the investigator's assessment) within 28 days prior to first administration of BI 764532 or planned during treatment period, e.g. hip replacement Any documented active or suspected malignancy or history of malignancy within 5 years prior to Screening (other than the target indication or well differentiated neuroendocrine tumour (NET) stages of the target indication in case of transformed tumors), except for appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix Further exclusion criteria apply.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Sequential Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Part B: BI 764532 + carboplatin + etoposide
Drug: BI 764532
BI 764532
Other Names:
  • Obrixtamig
Drug: Carboplatin
Standard of care
Drug: Etoposide
Standard of care
Experimental: Part B: BI 764532 + cisplatin + etoposide
Drug: BI 764532
BI 764532
Other Names:
  • Obrixtamig
Drug: Cisplatin
Standard of care
Drug: Etoposide
Standard of care
Experimental: Part A1: BI 764532 low dose + carboplatin + etoposide
Drug: BI 764532
BI 764532
Other Names:
  • Obrixtamig
Drug: Carboplatin
Standard of care
Drug: Etoposide
Standard of care
Experimental: Part A1: BI 764532 medium dose + carboplatin + etoposide
Drug: BI 764532
BI 764532
Other Names:
  • Obrixtamig
Drug: Carboplatin
Standard of care
Drug: Etoposide
Standard of care
Experimental: Part A1: BI 764532 high dose + carboplatin + etoposide
Drug: BI 764532
BI 764532
Other Names:
  • Obrixtamig
Drug: Carboplatin
Standard of care
Drug: Etoposide
Standard of care
Experimental: Part A2: BI 764532 + carboplatin + etoposide
Drug: BI 764532
BI 764532
Other Names:
  • Obrixtamig
Drug: Carboplatin
Standard of care
Drug: Etoposide
Standard of care

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Part B: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period
Time Frame: Up to 36 months.
Up to 36 months.
Part A1: Occurrence of dose-limiting toxicities (DLTs) in the maximum tolerated dose (MTD) evaluation period
Time Frame: Up to 21 days.
Up to 21 days.
Part A2: Reduced monitoring: the occurrence of DLTs during the on-treatment period
Time Frame: Up to 36 months.
Up to 36 months.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Part B: Objective response (OR)
Time Frame: Up to 36 months.
Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 (based on investigator's assessment) from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
Up to 36 months.
Part B: Duration of response (DoR)
Time Frame: Up to 36 months.
Duration of response (DoR), defined as the time from first documented confirmed objective response (OR) until the earliest date of disease progression or death among patients with confirmed objective response.
Up to 36 months.
Part A1: Occurrence of dose-limiting toxicities (DLTs) during the on-treatment period
Time Frame: Up to 36 months.
Up to 36 months.
Part A1: Occurrence of adverse events (AEs) during the on-treatment period
Time Frame: Up to 36 months.
Up to 36 months.
Part A2: Occurrence of adverse events (AEs) during the on-treatment period
Time Frame: Up to 36 months.
Up to 36 months.
Part A2: Objective response (OR)
Time Frame: Up to 36 months.
Objective response (OR), defined as a best overall response of confirmed complete response (CR) or confirmed partial response (PR) according to RECIST 1.1 (based on investigator's assessment) from the date of treatment start until the earliest date of disease progression, death, or last evaluable tumour assessment before start of subsequent anti-cancer therapy, loss to follow-up, or withdrawal of consent.
Up to 36 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Boehringer Ingelheim

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 22, 2024

Primary Completion (Estimated)

February 9, 2027

Study Completion (Estimated)

April 25, 2027

Study Registration Dates

First Submitted

November 10, 2023

First Submitted That Met QC Criteria

November 10, 2023

First Posted (Actual)

November 15, 2023

Study Record Updates

Last Update Posted (Actual)

May 27, 2026

Last Update Submitted That Met QC Criteria

May 26, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 1438-0007
  • U1111-1292-1400 (Registry Identifier: WHO Registry)
  • 2023-505870-13-00 (Registry Identifier: CTIS (EU))

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization).

For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Neuroendocrine Neoplasms

Clinical Trials on BI 764532

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Sweden

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe